Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2013 - 06 - 18

18/06/2013 - MENARINI GROUP announces agreement with GILEAD SCIENCES

MENARINI GROUP announces agreement with GILEAD SCIENCES
to commercialize Ranexa® (ranolazine) in 50 new countries


Menarini Group, the leading Italian pharmaceutical company in the world, ranking 17th in Europe and 34th in the world (IMS World Review 2012) is pleased to announce the signing of an exclusive long-term agreement with Gilead Sciences, Inc. to commercialize Ranexa® (ranolazine), an antianginal agent, in 50 new countries including China, India, Australia and New Zealand.

Menarini and Gilead are already in partnership in 68 countries in Europe, Commonwealth of Independent States (CIS) and South America. Ranexa is already commercialized by Menarini in 23 territories. In these territories, Ranexa, is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

Ranexa was approved by the U.S. Food and Drug Administration in 2006 and by the European Medicine Agency in 2008.

Based on IMS 2012 data, the EU reconstructed antianginal market (C01D+C01E: only long acting nitrates) is valued at € 370 million (+5% ppg) and 33 million units (-3.3% ppg) in 2012.

Commenting on the deal, Alberto Giovanni Aleotti, Vice Chairman of Menarini Group said: “We are delighted and honored to further strengthen our long-term partnership with Gilead to help address the needs of angina patients in these new territories, in particular the Asia Pacific region.”

About Menarini Group

Menarini is an international pharmaceutical company with over 16,000 employees worldwide and a presence in more than 100 countries in Europe, Asia, Latin America, Africa and the Middle East, and has a 2012 turnover of over €3 billion.
Research and internationalization represent the main areas of strategic development for its future. The Group has 14 manufacturing sites located in Italy and abroad where over 545 million packages/year are produced and distributed throughout the five continents, thus allowing Menarini to contribute to the health of patients all over the world with its high quality standards.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.
For more information on Gilead, please visit the company’s website at